April 5, 2012
/PRNewswire/ -- The U.S. Patent and Trademark Office has granted patent #8,133,917 pertaining to the ingredient pterostilbene, which is licensed exclusively to
(OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food & beverage, cosmetic and pharmaceutical industries, and marketer of
), its new line of dietary supplements.
This is the first ChromaDex-licensed patent issued for pterostilbene, while several more patents are pending.
The three key claims of the pterostilbene patent, which encompass both the nutraceutical market and the pharmaceuticals market, relate to:
- A method of lowering lipid levels and to treat or reduce the risk of dyslipidemias in an individual through an effective amount of edible nutraceutical composition consisting of isolated or chemically-synthesized pterostilbene and a nutraceutically acceptable carrier;
- A method of lowering lipid levels in an individual through an effective amount of edible pharmaceutical composition consisting of isolated or chemically-synthesized pterostilbene and a pharmaceutically acceptable carrier; and
- A method to treat or reduce the risk of dyslipidemias in an individual at risk of cardiovascular disease through an effective amount of edible pharmaceutical composition consisting of isolated or chemically-synthesized pterostilbene and a pharmaceutically acceptable carrier.
The patent application was initially filed in
by the U.S. Department of Agriculture. Subsequently, ChromaDex was granted an exclusive worldwide license to all rights in this patent of pterostilbene from the
University of Mississippi
and the Agricultural Research Service, which is the principal intramural scientific agency of the U.S. Department of Agriculture. The term of the license is up to and including the expiration of various pterostilbene patents and patents pending held by the licensors.
ChromaDex's proprietary pterostilbene, branded as
, was named the
2010 North American Most Promising Ingredient of the Year
by the independent research company Frost & Sullivan and is the key novel ingredient in BluScience, ChromaDex's new line of dietary supplements.
Pterostilbene has superior biological activity, better oral bioavailability and metabolizes more slowly in the body than other antioxidant polyphenols (phytochemicals that tend to prevent or neutralize the damaging effects of free radicals), allowing more time for its antioxidant activities to act. Along with a number of other effects, pterostilbene has shown great promise for supporting cardiovascular health, cognitive function and anti-aging.